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EndobioticsThe pregnane X receptor (PXR, NR1I2) is a ligand activated transcription factor that belongs to the nuclear
hormone receptor (NR) superfamily. PXR is highly expressed in the liver and intestine, but low levels of
expression have also been found inmany other tissues. PXR plays an integral role in xenobiotic and endobiotic
metabolism by regulating the expression of drug-metabolizing enzymes and transporters, as well as genes
implicated in the metabolism of endobiotics. PXR exerts its transcriptional regulation by binding to its DNA
response elements as a heterodimer with the retinoid X receptor (RXR) and recruitment of a host of
coactivators. The biological and physiological implications of PXR activation are broad, ranging from drug
metabolism and drug–drug interactions to the homeostasis of numerous endobiotics, such as glucose, lipids,
steroids, bile acids, bilirubin, retinoic acid, and bone minerals. The purpose of this article is to provide an
overview on the transcriptional circuits and metabolic relevance controlled by PXR. This article is part of a
Special Issue entitled: Translating Nuclear Receptors from Health to Disease.g–drug interaction; G6Pase,
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1.1. Discovery of PXR
The pregnane X receptor (PXR, NR1I2) belongs to the nuclear
hormone receptor (NR) superfamily of ligand activated transcription
factors [1]. PXR has been shown to play an essential role in xenobiotic
metabolism in humans, mice, rats, and rabbits [2–5]. Subsequent
studies have strongly suggested that PXR also plays an important role
in endobiotic metabolism in humans, mice, and rats [6–16]. The
mouse PXR (mPXR) was ﬁrst discovered and cloned in 1998 based on
sequence homology with other NRs and was found to be activated by
a variety of compounds, including natural and synthetic glucocorti-
coids, steroids, pregnane derivatives, antiglucocorticoids, macrocyclic
antibiotics, antifungals, and herbal extracts [1,3,17–21]. The human
PXR (hPXR) ortholog was subsequently reported as the steroid and
xenobiotic receptor (SXR) and pregnane activated receptor (PAR),
both exhibiting structural features and activation patterns similar tomPXR [19,20]. SXR/PAR was later conﬁrmed to be orthologous to
mPXR by Xie and colleagues via the gene replacement experiment
with the PXR knockout mice [22]. PXR has since been cloned from a
wide array of species, including mammals, birds, and ﬁsh [3,18–
21,23–25].
The structural organization of PXR follows that of a typical NR
which includes an NH2 - terminal ligand independent activation
function domain (AF-1, A/B region), a highly conserved DNA binding
domain (DBD, C region), a less conserved hinge domain (D region),
followed by a C-terminal ligand binding domain (LBD, E region) and
an activation function 2 domain (AF-2, F region) [26–30].
1.2. PXR's mode of action
When bound to and activated by ligands, PXR translocates from
the cytoplasm to the nucleus of the cells [31]. PXR then binds to its
DNA response elements as a heterodimer with the retinoid X receptor
(RXR). PXR is also capable of recruiting a host of coactivators which
includes members of the p160 family of coactivators such as steroid
receptor coactivators 1 (SRC-1), TIF/GRIP (SRC-2), and peroxisome
proliferator activated receptor γ coactivator 1α (PGC-1α) [32–34].
The DBD of PXR facilitates DNA binding speciﬁcity via two highly
conserved zinc ﬁnger motifs as well as a P-Box motif and D-Box motif
which allow the receptor to target and bind its xenobiotic response
elements (XREs) located in the 5′ promoter region of PXR target genes
[35]. PXR can bind to a variety of DNA response elements containing
two copies of the half site consensus sequence AG(G/T)TCA with
various spacing, which includes direct repeats DR-3, DR-4, and DR-5,
and everted repeats ER-6 and ER-8 [28].
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2.1. Regulation of Phase I enzymes
Functional characterization of PXR has shown that this receptor
acts as a xenosensor, playing a major role in protecting organisms
from exogenous chemical insults. PXR is highly expressed in the liver,
intestine, and kidneys, but low levels have also been found in the
peripheral blood monocytes, blood brain barrier, uterus, ovary, pla-
centa, breast, osteoclasts, heart, adrenal glands, bone marrow, and
speciﬁc brain regions of various species [23,36–40]. Given such a
broad range of expression pattern, PXR is well suited to accommodate
its metabolic role through the induction of metabolizing/detoxifying
enzymes and transporters.
The metabolism of exogenous and endogenous compounds is
quintessential for normal physiological functioning of any living
organism. PXR is capable of modulating this process through induction
of the major Phase I cytochromes P450 enzymes (CYPs). CYPs are a
superfamily of heme-dependent monooxygenases, which catalyze the
ﬁrst step of detoxiﬁcation of aliphatic or lipophillic compounds [41,42].
Highly expressed in the liver and intestine [41], CYPS use hydroxylation
and/or oxidation reactions to convert target compounds into more
soluble derivatives that are easier to excrete from the body [42].
Activation of PXRhas been shown to lead to the transcription of a host of
CYP genes in humans and rodents, including CYP3A4, CYP3A23,
CYP3a11, CYP2B6, Cyp2b9, Cyp2c55, CYP2C8, CYP2C9, CYP2C19, and
CYP1A [18,37,43–47].
It is apparent that since PXR controls the transcription of an array
of CYPs, this receptor must be activated by a commensurate number
of xenobiotic compounds. This is in fact the case: hPXR has been
shown to be activated by a plethora of pharmaceutical drugs that
include rifampicin (RIF), rifaximin [48], clotrimazole [3], dexameth-
asone [18], lovastatin [18] and metyrapone [49] to name a few. PXR is
also activated by a variety of environmental pollutants such as 1,1,1-
trichloro-2,2-bis(p-chlorophenyl)ethane (DDT), di-n-butyl phthalate
(DBP), chlordane, dieldrin, and endosulfan [50–52]. Finally, PXR can
be activated by a variety of medicinal compounds derived from herbal
sources including Schisandra chinensis (anti-perspiration), Piper
methysticum (chloraseptic), and Agauria salicifolia (arrhythmia) [53].
The ligand-dependent PXR activation has been shown to be species
speciﬁc at times. For example, in humans and rabbits the antibiotic RIF
is a potent PXR activator. However, the same drug has little effect on
the mouse or rat PXR. In contrast, the synthetic antiglucocorticoid
pregnenolone-16α-carbonitrile (PCN) can activate the mouse and rat
PXR but has no effect on hPXR. These species–species differences
represent a challenge for pharmaceutical companies attempting to
select appropriate animal models to evaluate candidate drugs. The
same notion has also led to the initial creation and characterization of
the hPXR humanized mice [22].
2.2. Regulation of Phase II enzymes
PXR also can regulate the expression of Phase II drug-metabolizing
enzymes, including UDP-glucuronosyl transferase (UGT), sulfotrans-
ferase (SULT) and glutathione S-transferase (GST) enzymes [54].
Phase II metabolic transformations are often, but do not have to be,
preceded by Phase I oxidation reactionswhich expose or add sites that
are ideal for Phase II conjugates. The Phase II metabolic enzymes add
polar molecules onto xenobiotics and endobiotics, producing water-
soluble, non-toxic metabolites amenable to biliary and/or urinary
excretion [55]. Indeed, a major consequence of PXR-mediated Phase II
metabolic enzyme regulation is the metabolism and detoxiﬁcation of
bile acids, estrogens, thyroxin, xenobiotics, and carcinogens [56].
UGTs are central Phase II metabolic enzymes which often have
distinct as well as overlapping substrates [57]. In humans, 19 enzymes
exist which contribute extensively to metabolism by catalyzing theaddition of a UDP-glucuronic acid to endo- and xenobiotics, enhancing
their water solubility and elimination [57,58]. PXR activation by
carbamazepin, RIF, dexamethasone and phenytoin has been linked to
the transcriptional activation of several UGTs, including UGT1A1,
UGT1A6, UGT1A3 and UGT1A4 [56,57,59,60]. These UGT isoforms are
also responsible for themetabolismof a plethora of other drugs such as
lamotrigine, olanzapine, retigabine, irinotecan/SN38, acetaminophen,
cyproheptadine, nicotine and imipramine, as well as carcinogens such
as 4-nitrophenol and 4-OH-PhIP, benzo[a]pyrene [56,57,61,62].
SULT enzyme activities represent another important Phase II
pathway of metabolism. SULTs facilitate xenobiotic metabolism by
catalyzing the addition of sulfate conjugates on drug molecules leading
to more water soluble compounds [63]. In mice, PXR activation by PCN
has been shown to upregulate the transcription of several SULT isoforms
including Sult1a1, Sult2a1, and Sult5a1 [64]. The role of PXR in human
regulation of SULTs in response to xenobiotics is loosely established.
Treatment with dexamethasone has been shown to upregulate
SULT2A1 in human liver cells, but rifampicin treatment has been
shown to have both inductive and suppressive effects [65–67].
GSTs are alsomajor enzymes in Phase IImetabolism, aswell asmany
other cytoprotective pathways. GSTs protect cells, organelles, and
macromolecules from chemical and oxidative stress, and electrophiles.
GSTs catalyzenucleophilic attackvia reducedglutathione (GSH)onnon-
polar compounds containing an electrophilic carbon, rendering them
less reactive and more hydrophilic [68,69]. In mice, PXR activation by
spironolactone, dexamethasone, and PCN has been shown to induce
several GSTs including Gsta3, Gstm1, Gstm2, Gstm3, Gstm4, and MGst1
[69]. The effect of genetic activation of PXR on GST expression in
transgenicmicehas been shown tobeGST isoform-, gender-, and tissue-
speciﬁc. Human PXR has not been extensively shown to induce GSTs;
however, a recent report by Naspinski and colleagues correlated PXR
activation by benzo[a]pyrene with subsequent upregulation of several
GSTs including GSTA1, GSTA2 and GSTM1 [70].
2.3. Regulation of drug transporters
Drug disposition and metabolism are also regulated by an array of
cellular uptake and efﬂux transporters that control intestinal and
hepatic absorption, renal re-absorption, and biliary/urinary elimina-
tion. These transporters work in concert with Phase I and II enzymes.
The major xenobiotic transporters subject to PXR regulation include
the ATP binding cassette family (ABC) proteins expressed in hepa-
tocytes, enterocytes, kidney, and blood brain barrier that regulate
cellular export of drugs. Examples of PXR target ABC transporters
include the multidrug resistance 1 or P-glycoprotein (MDR1/P-gp),
multidrug resistance associated proteins (MRP2, MRP3, MRP4, and
MRP5), and breast cancer resistance protein (BCRP) [71–74]. The
organic anion transporting polypeptide family (SLC/OATP), which
regulates drug and endobiotic inﬂux/uptake into the liver, is also
regulated by PXR [75]. The known PXR target SLC/OATP genes include
SLCO1A2/OATP1A2, SLCO1B1/OATP1B1, and SLCO1B3/OATP1B3. Fi-
nally, the organic ion transporter family, particularly the organic
cation transporter SLC22A5/OCTN2, is proposed to have moderate
PXR related regulation [76].
2.4. Implication of PXR in drug–drug interactions (DDIs)
As previously discussed, CYPs play an integral role in Phase I
metabolism. Among CYP isoforms, the CYP3A subfamily is the most
abundant in the liver and also conveys broad substrate speciﬁcity [77].
In fact, CYP3As have been shown to be responsible for the metabolism
of over 50% of pharmaceuticals on the market today [77]. PXR has
been shown to be a major transcriptional regulator of CYP3As, and
because of this, it became increasingly apparent that the PXR-
mediated regulation of drug-metabolizing enzymes could be involved
in clinical DDIs. Such interactions occurwhen one drug accelerates the
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[78]. In addition, DDIs have been shown to cause decreased or absent
bioavailability for orally administered drugs and increased hepatic
clearance or accelerated formation of reactive metabolites, which can
lead to local or systemic toxicity [78]. The human CYP3A4 is induced
by PXR and has been shown clinically to be involved in possible drug–
drug interactions. An example is the effect of RIF, a hPXR agonist, on
the metabolism of the antihypertensive drug Verapamil [78]. Long-
term treatmentwith RIF caused increased hepatic and gastrointestinal
levels of CYP3A4, which led to the reduced oral bioavailability of (S)-
verapamil by 96%, and abolished the anti-hypertensive effect in patients
[78]. Another example was reported by Maglich and colleagues when
they demonstrated that the anxiolytic herb St. John'sWort could induce
CYP3A4 at low concentrations. This discovery explained prevalent
clinical data which showed increased metabolism and reduced efﬁcacy
of oral contraceptives, cyclosporin, and indinavir when taken with St.
John'sWort [79]. Unfortunately, these are not anecdotal occurrences, as
they have beendemonstrated clinically in an array of situations [80–85].
In the future, it is imperative to continue to use relevant animalmodels,
such as the hPXR humanizedmice [86], in order to fully understand the
pharmacokinetic proﬁle of PXR ligands and CYP substrates.
3. PXR in endobiotic metabolism
Although PXRwas originally characterized as a xenobiotic receptor, it
has been demonstrated that PXR has equal importance as an endobiotic
receptor. Many studies have revealed essential roles of PXR in glucose
and lipid metabolism, steroid hormone homeostasis, bile acid and
bilirubin detoxiﬁcation, vitamin metabolism and inﬂammation. As a
result, PXRactivationhasgreat implications inmanypatho-physiological
conditions.
3.1. PXR in glucose metabolism
Blood glucose is tightly controlled by insulin and glucagon through
gluconeogenesis, glycogenolysis, and glycogenesis. Glucose-6-
phosphatase (G6Pase) and phosphoenolpyruvate carboxykinase1
(PEPCK1) are rate-limiting enzymes in gluconeogenesis and glycogen-
olysis [87,88]. These genes are upregulated by glucagon and glucocorti-
coids. Glucagon increases the formation of intracellular cAMP, which
activates protein kinase A (PKA) to stimulate cAMP-response element-
binding protein (CREB) that binds to and regulates the transcription of
PEPCK1 and G6Pase [89,90]. Similarly, glucocorticoids induce PEPCK1
expression through a glucocorticoid response element [91]. On the
other hand, insulin suppresses gluconeogenesis by downregulating the
transcription of G6Pase and PEPCK1 [92]. The forkhead transcription
factor 1 (FoxO1) functions as an activator of G6Pase and PEPCK1 in the
absenceof insulin [92,93]. Uponbinding to an insulin response sequence
(IRS), insulin excludes FoxO1 from the nucleus through phosphatidy-
linositol3-kinase (PI3K)-Akt pathway [94], resulting in a repressed
expression of G6Pase and PEPCK1 and decreased glucose production.
PXR plays a role in hepatic gluconeogenesis. The expression of
PEPCK and G6Pase was reduced in VP-hPXR transgenic mice in which
the expression of an activated PXR (VP-PXR) was directed to the liver
[95]. The PXR agonist PCN downregulated G6Pase gene expression in
wild type but not PXR−/−mice [93]. Studies by Kodama and colleagues
[93] suggested cross-talk between PXR and CREB and FoxO1 in
regulating gluconeogenesis. They used a gel shift assay to show that
PXR directly interacted with CREB and prevented its binding to the
G6Pase gene promoter. Next, through a chromatin immunoprecipita-
tion (ChIP) assay they showed that treatment with PCN decreased
CREB binding to the promoter of G6Pase only in wild-type but not in
PXR−/−mice. Thus, by forming a complex with phosphorylated CREB,
ligand activated PXR repressed CREB-mediated gene transcription and
gluconeogenesis. Finally, PXR inhibited the binding of FoxO1 to IRS by
direct interaction with FoxO1, as demonstrated by both gel shift andGST pull-down assays. A reporter gene assay also showed that FoxO1-
IRS activity was repressed by PXR activation [96]. Therefore, it seems
that ligand activated PXR directly interacts with FoxO1, which
prevents FoxO1 from binding to IRS, leading to the suppression of
G6Pase and PEPCK1 gene expression and gluconeogenesis [97]. The
hepatocyte nuclear factor 4α (HNF4α) also positively regulates
gluconeogenesis with the nuclear receptor coactivator PGC-1α. Bhalla
and colleagues showed that PXR could compete with HNF4α for PGC-
1α and thus suppress gluconeogenesis [9].
3.2. PXR in lipid metabolism
Triglycerides and fatty acids are also vital metabolic fuels. Lipid
homeostasis centers on balancing lipid uptake and synthesis with
lipid catabolism and secretion. When glucose and fatty acids exceed
the body's energy needs, they are converted to triglycerides in the
liver for storage. During fasting or exercise, fatty acid β-oxidation and
ketogenesis are increased in adipocytes to enhance ketone body
synthesis and to provide energy. The sterol regulatory element-
binding protein 1c (SREBP-1c) is a master regulator of lipogenesis.
Several nuclear receptors, such as LXR [98], HNF-4 [99] and LRH-1
[100], orchestrate lipid homeostasis through regulating the transcrip-
tional activity of SREBP.
Interestingly, Zhou and colleagues showed that PXR induced
lipogenesis in an SREBP-independent manner [95]. VP-PXR transgenic
mice showed increased triglyceride accumulation in the liver, which
was linked to upregulation of fatty acid translocase CD36 and several
other accessory lipogenic enzymes, including SCD-1 and long-chain
free fatty acid elongase. CD36 is a scavenger receptor with broad
ligand speciﬁcity. Activation of CD36 facilitates free fatty acid uptake
from the circulation [101] and might contribute to hepatic steatosis.
Correlation between CD36 levels and triglyceride storage and
secretion suggests the causative role of CD36 in hepatic steatosis
[102]. In fact, PXR is both necessary and sufﬁcient for activation
of CD36 transcription. Further studies established CD36 as a direct
PXR transcriptional target [95]. CD36 expression can also be positively
regulated by LXR and PPARγ. Therefore, CD36 appears to be a shared
transcriptional target of LXR, PXR and PPARγ in their regulation of
lipid homeostasis [103].
Two key enzymes involved in β-oxidation and ketogenesis are
carnitine palmitoyltransferase 1A (CPT1A) and mitochondrial 3-
hydroxy-3-methyl-glutarate-CoA synthase 2 (HMGCS2) [104,105].
In the absence of insulin, a winged-helix/forkhead transcription factor
FoxA2 stimulates the transcription of CPT1A and HMGCS2 [106].
Insulin induces the phosphorylation and nuclear exclusion of FoxA2,
resulting in inactivation of FoxA2 and suppression of CPT1A and
HMGCS2 transcription [107]. Nakamura and colleagues showed that
PCN decreased transcription of Cpt1a and Hmgcs2 in wild-type, but
not in PXR knockout mice. The underlying mechanism seemed to be
direct binding of PXR to FoxA2 and suppression of Cpt1a and Hmgcs2
gene activation [108].
Cholesterol is essential to form cell membranes, bile acids and
steroid hormones. On the other hand, oxidized cholesterol metabolites
are cytotoxic and represent risk factors for atherosclerosis [109].
Therefore, cholesterol detoxiﬁcation is crucial to protect the body
from excess cholesterol. The mitochondrial sterol 27-hydroxylase
(CYP27A1) is required for the cleavage and hydroxylation of cholesterol
in most tissues [110,111]. Li et al. [112] showed that PXR activates
CYP27A1, aswell as cholesterol efﬂux transporters ABCA1 and ABCG1 in
intestinal cells. The “good cholesterol” HDL and its major constituent
apolipoprotein A-I (ApoA-I) are involved in reverse cholesterol
transport and have been associated with a reduced risk of atheroscle-
rosis. ApoA-I andHDL cholesterol levelswere elevated by PXR agonist in
wild-type, but not in PXR−/− mice [10]. Cholic acid mediated down-
regulation of HDL cholesterol and plasma ApoA-1 was abolished in
human PXR transgenic mice [113].
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atherogenic role of PXR. Activation of PXR decreased the expression of
ABCA1 in hepatocytes [114]. Clinically used PXR activating drugs
caused hyperlipidemia in some patient populations [11,115,116].
Future studies are necessary to further deﬁne the role of PXR in the
pathogenesis of hyperlipidemia.
3.3. PXR in glucocorticoid and mineralocorticoid homeostasis
Studies by Zhai et al. [117] showed the importance of PXR in adrenal
steroidhomeostasis. Both genetic and pharmacological activation of PXR
increased plasma levels of corticosterone and aldosterone. This increase
was accompanied by activation of adrenal steroidogenic enzymes, such
asCYP11a1, CYP11b1, CYP11b2, and 3β-hydroxysteroid dehydrogenase
(3β-HSD). Interestingly, the PXR transgenic mice exhibited normal
ACTH secretion in pituitary, and intact suppression of dexamethasone
by corticosterone, indicating a functional hypothalamus–pituitary–
adrenal axis in spite of severely disrupted adrenal steroidhomeostasis.
Consistentwith theseobservations, several clinical studies reported that
rifampicin increased steroid secretion in urine andmay have resulted in
misdiagnosis of Cushing's syndrome [118,119]. Therefore, PXR has a
potential to disrupt endocrine homeostasis, and it may be broadly
implicated in drug–hormone interactions.
3.4. PXR in androgen metabolism
The androgen–androgen receptor signaling pathway plays an
important role in the initiation and progression of prostate cancer.
Accordingly, androgen deprivation has been the most effective
endocrine therapy for hormone-dependent prostate cancer. There
are at least two major PXR target genes, CYP3A and SULT2A1, which
are known to play a role in the metabolic deactivation of androgens.
CYP3A is the key enzyme in catalyzing hydroxylation of testosterone
and progesterone, leading to inactive hormones [120]. Dehydroepian-
drosterone (DHEA) sulfotransferase (SULT2A1) is the primary SULT
isoform responsible for androgen sulfonation [121]. Based on these
notions, Zhang and colleagues recently reported a novel PXR-
mediated and metabolism-based androgen deprivation [122]. In this
study, the authors showed that activation of PXR lowered androgenic
activity and inhibited androgen-dependent prostate regeneration in
castrated male mice that received daily injections of testosterone by
inducing the expression of CYP3As and SULT2A1. In human prostate
cancer cells, treatment with the PXR agonist RIF inhibited androgen-
dependent proliferation of LAPC-4 cells, but had little effect on the
growth of the androgen-independent isogenic LA99 cells. Down-
regulation of PXR or SULT2A1 in LAPC-4 cells by shRNA or siRNA
abolished the RIF effect, indicating that the inhibitory effect of RIF on
androgens was PXR- and SULT2A1-dependent. PXR may represent a
novel therapeutic target to lower androgen activity andmay aid in the
treatment and prevention of hormone-dependent prostate cancer.
3.5. PXR in bile acid and bilirubin detoxiﬁcation
Bile acids, synthesized in the liver, are end products of cholesterol
catabolism and represent the primary pathway for cholesterol
elimination from our bodies [123]. When excreted into the intestine,
bile acids promote the absorption of cholesterol and fat-soluble
vitamins. However, excess bile acids are cytotoxic and can lead to
pathological cholestasis [124]. Therefore, bile acid levels need to be
tightly regulated to protect the human body from their toxic effects.
PXR plays a critical role in bile acid detoxiﬁcation [12,14]. PXR
agonist PCN reduced lithocholic acid (LCA) induced toxicity in wild-
type, but not in PXR knockout mice. PXR transgenic mice were also
resistant to LCA toxicity [12]. The protective effect of PXR can be
explained by its regulation of genes involved in bile acid metabolism.
PXR induced the expression of CYP3A that is essential for bile acidhydroxylation and excretion [14]. The Phase II enzyme SULT2A is also a
PXR target gene that contributes to bile acid detoxiﬁcation [47]. In
addition to bile acid synthesis and metabolism, PXR also regulates the
expression of bile acid transporters, such asMRP2 [125] andOATP2 [14].
There were also reports suggesting that PXR may play a role in the
regulation of CYP7A1. It was reported that ligand activated PXR
reduced the expression of CYP7A1 without affecting SHP expression
in mice [14]. However, hPXR can regulate SHP expression directly in
HepG2 cells [126]. PXR has also been reported as a FXR target gene
[127]. Together, these results suggested a close evolutionary relation-
ship between PXR and FXR in protecting the human body from bile
acid toxicity.
Bilirubin is the breakdown product of heme proteins. Conjugation
of bilirubin by UGT converts the neurotoxic unconjugated bilirubin to
nontoxic bilirubin glucuronide. It has been reported that activation of
PXR prevented experimental hyperbilirubinemia in mice [56]. PXR
activates the transcription of UGT1A1 [13] and several other genes
critically involved in bilirubin detoxiﬁcation, such as OATP2 [14] and
MRP2 [125]. OATP2 mediates bilirubin uptake from blood into liver,
whereas MRP2 facilitates the excretion of conjugated bilirubin to bile
canaliculus. As a result, PXR ligands may represent potential
therapeutic agents in treating hyperbilirubinemia.
3.6. PXR in vitamin metabolism and bone mineral homeostasis
Vitamin K2 is critical for bone formation and has been clinically
used to treat osteoporosis. It has been reported that vitamin K2 can
activate PXR and stimulate PXR target gene expression. Treatment of
osteosarcoma cells with vitamin K2 increased themRNA expression of
osteoblast markers bone alkaline phosphatase, osteoprotegerin,
osteopontin, and matrix Gla protein [128]. Vitamin K2 induced the
expression of bonemarkers in primary osteocytes fromwild-type, but
not PXR−/− mice [128]. Ichikawa et al. [129] identiﬁed several PXR
target genes with bone related functions in osteoblastic cells. Igarashi
et al. [130] showed that activation of PXR by vitamin K2 induced the
expression of osteoblastogenic transcription factor Msh homeobox 2,
which is involved in osteoblast differentiation.
Calcium is amajor component inbonedevelopment andmaintenance.
Calcium absorption and excretion are regulated by vitamin D, whose
active metabolite 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) binds to the
vitamin D receptor (VDR) [131]. VDR activates 25-hydroxyvitamin D
(3)-24-hydroxylase (CYP24)-mediated 24-hydroxylation, which is
critical in 1,25(OH)2D3 metabolism. Pascussi et al. [132] reported
that activation of PXR upregulated CYP24 gene expression.
However, Zhou et al. [133] showed that PXR activation inhibited
CYP24 promoter activity. Although controversial, these results
suggested a potential role of PXR in bone homeostasis, which
warrants further investigation. Ligand activated PXR also suppresses
the transcription of CYP2D25, an important hydroxylase in 1, 25(OH)
2D3 biosynthesis. It has been known for decades that prolonged
treatment with anticonvulsant drugs may result in vitamin D
deﬁciency or osteomalacia in patients [134,135]. Since many
anticonvulsant drugs, such as carbamazepine and phenobarbital,
are PXR ligands, these results urge caution in preventing drug-
induced osteomalacia in patients.
Vitamin E is often taken as a dietary supplement for antioxidation
purpose. Vitamin E is metabolized by CYPs mediated ω-oxidation
[136], followed by β-oxidation, conjugation including glucuronidation
and sulfation [137,138], and then excretion [139,140]. These process-
es are facilitated by an array of enzymes and transporters that happen
to be PXR target genes. It was reported that vitamin E can activate PXR
[141,142], and therefore may regulate xenobiotic detoxifying genes
involved in its own metabolism. The study by Landes et al. [141]
showed that PXR can be activated by several forms of vitamin E in a
reporter gene assay. The most potent PXR activator γ-tocotrienol
can induce the expression of endogenous CYP3A4 as efﬁcacious as
Fig. 1. Summary of the transcriptional circuits and metabolic relevance controlled by
PXR. PXR, pregnane X receptor; RXR, retinoid X receptor.
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decreased upon PCN treatment in wild type but not PXR−/− mice,
whichwas suggested due to PXR-mediated downregulation of hepatic
sterol carrier protein 2 and attenuated β-oxidation [8]. These ﬁndings
raise the concern of potential drug–drug interactions between
vitamin E and PXR regulators, which requires further studies.
3.7. PXR in retinoic acid metabolism
Retinoic acid (RA) is the metabolite of vitamin A that binds to and
activates the retinoic acid receptor (RAR). RAR forms a heterodimer
with RXR and activates the transcription of genes associated with cell
differentiation [143] and apoptosis [144], leading to inhibition of cell
growth. Therefore, RAs havebeenused or tested as anti-cancer agents in
several human cancer types [145]. However, RA resistance represents a
major limit to its clinical use,whichmightbeexplainedat least inpart by
the co-administration of a PXR agonist. Ligand activated PXR can induce
expression of CYP3A and transporters such as MDR1A, MRP3 and
OATP2, which accelerate RA metabolism [146]. It has been suggested
that PXR antagonists might be useful in preventing RA resistance.
3.8. PXR in inﬂammation
A negative correlation between infectious disease/inﬂammation
and drug metabolism capacity has been long suggested [147]. In
understanding the molecular mechanisms behind this correlation,
Teng et al. showed that treatment of wild typemice with IL-6 caused a
marked decrease in PXR protein level, as well the mRNA expression of
PXR and its target genes Mrp2, Bsep, and Cyp3a11. This reduction was
not seen in PXR−/−mice subjected to the same treatment, suggesting
that this reduction was mediated by PXR. The same group showed
that IL-6 could attenuate the upregulation of PXR and its target genes
after PCN treatment inwild-typemice [148]. Additionally, Beigneux et
al. showed that induction of a speciﬁc type of inﬂammation called
acute phase response by lipopolysaccharide (LPS) caused a marked
decrease in the mRNA expression of PXR and its target genes in the
liver of wild-type mice [149].
Reciprocally, treatment of human patients with rifampicin is
known to activate PXR, leading to increased expression of PXR target
genes. It is also known that patients treated with rifampicin showed
marked immunosuppression. Zhou et al. showed in vivo and in vitro
that activation of PXR via rifampicin can attenuate NF-κb proteins,
which are important in facilitating immune response and inﬂamma-
tion. Moreover, activation of NF-κb was shown to inhibit PXR, and
inhibition of NF-κb enhanced PXR activity. The same group also
showed that PXR−/− mice had increased small bowel inﬂammation
and expression of NF-κb target genes [150]. Taken together, inhibition
of PXR may be one mechanism of inﬂammation responsive repression
of drug metabolism, whereas activation of PXR may be one
mechanism for the drug-responsive immunosuppression.
4. Conclusions and perspectives
As summarized in Fig. 1, many xenobiotics and endobiotics, as well
as their metabolites can activate PXR. Subsequently, the activated PXR
regulates the transcription of key enzymes involved in the metabo-
lism of xenobiotics and endobiotics. Although the endobiotic func-
tions of PXR have been appreciated, identiﬁcation of physiologically
relevant endogenous ligands for PXR will be beneﬁcial in under-
standing the role of PXR as an endobiotic sensor. As we learn more
about the roles of PXR in xenobiotic and endobiotic gene regulation, it
remains to be determined whether the regulatory functions of PXR
can be taken advantage of in preventing and treating human diseases.
The role of PXR in xenobiotic metabolism is vast, nuanced, and
extremely important. With the burgeoning number of pharmaceu-
ticals on the market that are PXR ligands, more research must be donetoward investigating receptor-mediated drug–drug interactions. The
development of humanized mice offers a promise in using the in vivo
model to predict PXR-mediated drug–drug interactions.
In addition, polymorphisms of PXR and its major transcriptional
targets such as CYP3A4 andMDR1 can affect xenobiotic and endobiotic
metabolism. Considering the broad and complex transcription
network controlled by PXR, the genetic variation of PXR might have
broad implications in physiology and diseases [30].To date, many
splice variants of PXR have been identiﬁed and even more single
nucleotide polymorphisms (SNPs) have been reported [151]. These
polymorphisms exist in the coding or non-coding regions of the PXR
gene, and several polymorphisms are associated with functional
changes of PXR [30]. Future studies are necessary to assess metabolic
differences in populations of different PXR genotypes [151].
Today's medicine and biomedical research are at the interface of the
old standardized approach and the new pharmacogenetically person-
alized future. In order for scientists and doctors to make headway into
the future, it will be important to characterize genetics-basedmetabolic
differences. Since its inception, the importance of PXR in xenobiotic and
endobiotic metabolism has been repeatedly redeﬁned. We have
discussed many of the metabolic circuits that can be controlled by
PXR and described how alterations in these pathways could have
substantial physiological consequences. As we move into the future, a
full genetic assessment of the metabolic characteristics of PXR is
imperative in order to further research thatmay lead to development of
novel drugs or improvements on current drug therapies.Acknowledgments
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